APU
REGN icon

Alpine Partners USVI’s Regeneron Pharmaceuticals REGN Stock Holding History

Alpine Partners USVI’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-3,224
Closed -$725K – 110
2013
Q2 		$725K Buy
+3,224
New +$751K 0.23% 72

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Alpine Partners USVI's REGN Position: Q3 2013 in Review

Alpine Partners USVI sold out of Regeneron Pharmaceuticals (REGN) in Q3 2013, closing a stake of 3,224 shares — an estimated $725K sold.

Alpine Partners USVI first reported a position in REGN in Q2 2013 and held it in 1 quarter. The position peaked at $725K in Q2 2013. 414 funds tracked by Wall St. Rank hold REGN as of Q3 2013.

  • Alpine Partners USVI reported no remaining Regeneron Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Alpine Partners USVI sold 3,224 Regeneron Pharmaceuticals shares in Q3 2013, an estimated $725K.
  • Alpine Partners USVI first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Alpine Partners USVI's Regeneron Pharmaceuticals position peaked at $725K in Q2 2013.
  • 414 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2013.

Based on Alpine Partners USVI's 13F filing for Q3 2013, filed 14 Nov 2013.